Arvinas (ARVN) Other Non-Current Liabilities (2017 - 2018)
Arvinas (ARVN) posted quarterly Other Non-Current Liabilities of $150000.0 for Q4 2018, up 194.76% year-over-year from $50888.0 in Q4 2017, and up 194.76% quarter-over-quarter from $50888.0 in Q4 2017.
Arvinas (ARVN) Other Non-Current Liabilities (2017 - 2018) Analysis & Trends
Arvinas' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $150000.0 for Q4 2018.
- In Q4 2018, Other Non-Current Liabilities rose 194.76% year-over-year to $150000.0; the TTM figure through Dec 2018 stood at $150000.0 (up 194.76% YoY), while the FY2018 annual figure was $150000.0, up 194.76% from the prior year.
- Other Non-Current Liabilities for Q4 2018 stood at $150000.0, up from $50888.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $150000.0 in Q4 2018, with the low at $50888.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arvinas | 585.74 Mn | 17.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 150,000.00 |
| Dec 31, 2017 | 50,888.00 |